RxDoctor Payments Data

Sandip Patel, MD

Internal Medicine · Toms River, NJNPI 1316225659

Payments from drug & device makers

$9,337in general payments, 2019–2025

Across 20 payments — averaging $466.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beigene Switzerland GmbH$9K
  • Johnson & Johnson$187
  • Biotissue Holdings Inc.$125
  • Tarsus Pharmaceuticals, Inc.$118
  • Exact Sciences$115
  • AbbVie$47
  • plus $120 from 7 others
$65in research payments, 2019–2025

Across 1 payment — averaging $65.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$65

What the payments were for

  • Consulting fees$8,62592%
  • Food & beverage$7128%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,337 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$279,624
Medicare patients
649
Services billed
3,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban770$345,923
IngrezzaValbenazine Tosylate14$117,946
JanuviaSitagliptin Phosphate203$112,989
XareltoRivaroxaban273$107,076
FarxigaDapagliflozin Propanediol159$84,573
Breo ElliptaFluticasone/Vilanterol125$54,120
TivicayDolutegravir Sodium20$46,967
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$40,782
EntrestoSacubitril/Valsartan34$29,758
CreonLipase/Protease/Amylase23$24,062
TradjentaLinagliptin36$23,663
OzempicSemaglutide11$23,066
RelistorMethylnaltrexone Bromide37$22,479
VraylarCariprazine Hcl15$21,634
Glatiramer Acetate36$19,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$187$107,076273 claims
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta$14$104,786209 claims
AbbVieCreon, Vraylar, Restasis, Linzess, Lumigan$47$75,031116 claims
NovartisEntresto$21$29,75834 claims
Novo NordiskOzempic$17$23,06611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Toms River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →